With a robust balance sheet, full exposure to the gold price and a clear path to organic growth, Westgold is committed to ...

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

bluebird bio, a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle and SK Capital Partners, LP ...

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital By Reuters May 14, 20257:11 AM PDTUpdated May 14, 2025 ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Two weeks after boosting resources at its Bluebird-South Junction mine near Meekatharra in Western Australia to 1.4 million ounces, Westgold Resources has doubled the all-important reserves that ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered ...